香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司（「香港結算」）對本公 告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本公告不得直接或間接於或向美國（包括其領土及屬地、美國任何州以及哥倫比亞特區）發佈、刊發或派發。本公 告並不構成或組成在美國境內或於任何其他司法權區購買或認購證券的任何要約或招攬的一部分。本公告所述證 券並無亦不會根據1933年美國證券法（經不時修訂）（「美國證券法」）或美國任何州或其他司法權區的證券法登記。 證券不得在美國境內提呈發售、出售、質押或以其他方式轉讓，惟獲豁免遵守美國證券法登記規定及符合任何適 用的州證券法則另作別論。證券根據美國證券法S規例以離岸交易的方式在美國境外提呈發售及出售。證券將不 會在美國公開發售。 本公告僅作說明用途，並不構成收購、購買或認購證券的邀請或要約。本公告並非招股章程。有意投資者在決定 是否投資所提呈發售的H股前，應細閱深圳市沃爾核材股份有限公司（「本公司」）刊發日期為2026年2月5日的招股 章程（「招股章程」） ...

Group 1 - Beijing Haizhi Technology Group Co., Ltd. (stock code: 2706) announced the results of its global offering, with the final offer price set at HKD 27.06 per share [1] - A total of 28,030,200 H-shares were offered in the global sale, including 2,803,200 shares for public offering in Hong Kong and 25,227,000 shares for international placement [1] - The total proceeds from the global offering are approximately HKD 760 million, with a net amount of about HKD 660 million after deducting estimated listing expenses [1] Group 2 - The Hong Kong public offering received 232,258 valid applications, resulting in a subscription rate of 5,065.06 times, while the international placement had a subscription rate of 8.39 times [1] - The offering did not trigger the reallocation mechanism, maintaining the initial distribution of 10% for the Hong Kong public offering and 90% for international placement [1] - Four cornerstone investors participated in the offering, collectively subscribing to 4,307,400 H-shares, which accounts for 15.37% of the total shares offered [2] Group 3 - The cornerstone investors include JSC International Investment Fund SPC (representing Etown SP) with 1,426,200 shares (5.09%), JINGSHENG HENGXING TECHNOLOGY PTE. LTD. with 1,152,400 shares (4.11%), and Infini Global Master Fund and Mega Prime Development Limited each with 864,400 shares (3.08%) [2] - The joint sponsors for the global offering are CMB International, BOC International, and Shenwan Hongyuan Hong Kong [2] - H-shares are expected to commence trading on the Hong Kong Stock Exchange on February 13, 2026, with a trading unit of 200 shares [2]

香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司 （「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表聲明，並明確表示概不 會就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 本公告不得直接或間接於或向美國（包括其領土及屬地、美國任何州以及哥倫比亞特區）發佈、 刊發或派發。本公告並不構成或組成在美國境內或於任何其他司法管轄區購買或認購發售股 份的任何要約或招攬的一部分。發售股份並無亦不會根據1933年美國《證券法》（經不時修訂） （「美國《證券法》」）或美國任何州或其他司法管轄區的證券法登記。發售股份不得在美國境內 提呈發售、出售、質押或以其他方式轉讓，除非已根據美國《證券法》的登記規定獲豁免，並已 符合任何州的適用證券法。發售股份根據美國《證券法》S規例在美國境外向非美籍人士投資者 或並非為美籍人士或為其利益進行收購的投資者提呈發售及出售。發售股份不會在美國公開發 售。 本公告僅作說明用途，並不構成收購、購買或認購證券的邀請或要約。本公告並非招股章程。 潛在投資者於決定是否投資所提呈發售的H股前，應閱覽北京海致科技集團股份有限 ...

香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司 （「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表 示概不就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 除本公告另有界定者外，本公告所用詞彙與牧原食品股份有限公司（「本公司」）日期為2026年1 月29日的招股章程（「招股章程」）所界定者具有相同涵義。本公告乃承本公司董事（「董事」）會 （「董事會」）之命而作出。董事會就本公告的準確性共同及個別承擔責任。 本公告僅供參考，並不構成收購、購買或認購任何證券的邀請或要約。本公告並非招股章程。 有意投資者於決定是否投資於發售股份前應閱覽招股章程，以獲得有關下文所述全球發售的詳 細資料。任何有關發售股份的投資決定應僅依賴招股章程所提供的資料作出。 本公告不會直接或間接於或向美國（包括其領土及屬地、美國任何州及哥倫比亞特區或法律禁 止此類發佈的任何其他司法權區）發佈、刊發或派發。本公告並不構成或組成在美國境內或於 任何其他司法權區購買或認購證券的任何要約或招攬的一部分。本公告所述證券並無亦不會根 據美國證券法或美國 ...

香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司 （「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表 示概不就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任 何責任。 本公告不得直接或間接於或向美國（包括其領土及屬地、美國任何州以及哥倫比亞特區）發佈、 刊發或派發。本公告並不構成或組成在美國境內或於任何其他司法管轄區購買或認購發售股 份的任何要約或招攬的一部分。東鵬飲料（集團）股份有限公司（「本公司」）並無亦不會根據《1940 年美國投資公司法》（經修訂）（「《美國投資公司法》」）登記。發售股份並無亦不會根據《1933年 美國證券法》（經修訂）（「《美國證券法》」）或美國任何州或其他司法管轄區的證券法登記。發 售股份不得在美國境內或向美國人士（定義見《美國證券法》S規例）提呈發售、出售、質押或 以其他方式轉讓，但根據《美國證券法》及《美國投資公司法》登記規定的一項豁免或在不受該 法登記規定規限的交易中則除外，並已符合任何州的適用證券法。發售股份(1)僅可根據《美 國證券法》第144A條或根據《美國證券法》及任何州的適 ...

Group 1 - The company Longqi Technology (603341) announced the results of its global offering, issuing a total of 52.2591 million H-shares [1] - The global offering raised approximately HKD 1.52 billion, with the share price set at HKD 31.00 per share [1] - The offering was heavily oversubscribed, with the Hong Kong public offering receiving 1,149.76 times subscription and the international offering receiving 9.02 times subscription [1] Group 2 - The Hong Kong public offering accounted for 10% of the total shares, while the international offering made up 90% [1] - The H-shares are expected to commence trading on the Hong Kong Stock Exchange on January 22, 2026, at 9:00 AM [1]

Core Viewpoint - The global offering of H-shares by the company has been successfully completed, raising approximately HKD 46.84 billion in total proceeds, with a net amount of about HKD 46.11 billion after listing expenses [1] Group 1: Offering Details - The company issued 28,915,800 H-shares at a final offer price of HKD 162.00 per share, with 10% allocated to the Hong Kong public offering and 90% to international placement [1] - The Hong Kong public offering received 148,419 valid applications, resulting in a subscription rate of 542.22 times, while the international offering had 177 participants with a subscription rate of 18.52 times [1] Group 2: Investor Participation - The company secured subscriptions from 16 cornerstone investors for a total of 14,394,300 H-shares, representing 49.78% of the global offering [1] - Additionally, the company has been granted an over-allotment option for 4,337,300 H-shares [1] Group 3: Trading Information - The H-shares are set to commence trading on the Hong Kong Stock Exchange on January 13, 2026, under the stock code 3986 [1]

Group 1 - The company announced a global offering of 45.8 million H-shares, with 4.58 million shares allocated for public offering in Hong Kong, accounting for 10% of the total [1] - The international offering consists of 41.22 million shares, representing 90% of the total [1] - The offering price per share is set at HKD 104.80, with expected net proceeds of approximately HKD 4.742 billion [1] Group 2 - The H-shares are scheduled to be listed on the main board of the Hong Kong Stock Exchange in 2026 [1] - Prior to the offering, the total share capital of the company is 1.21 billion shares, which will increase to 1.256 billion shares if the over-allotment option is not exercised [1] - If the over-allotment option is fully exercised, the total share capital will rise to 1.263 billion shares, with the shareholding ratios for A-shares and H-shares being 95.83% and 4.17% respectively [1]

Group 1 - The company,豪威集团, announced the results of its global offering, issuing 45.8 million H-shares, with 10% allocated for public offering in Hong Kong and 90% for international offering [1] - The offer price per share was set at HKD 104.8, resulting in net proceeds of approximately HKD 4.693 billion from the global offering [1] - The Hong Kong public offering was oversubscribed by 9.28 times, while the international offering was oversubscribed by 9.73 times [1] Group 2 - The H-shares are expected to commence trading on the Hong Kong Stock Exchange at 9:00 AM on January 12, 2026 [1]

Core Viewpoint - Rebio Biotech-B (06938) has successfully completed its global offering, raising approximately HKD 1.702 billion through the issuance of 31.6104 million H-shares at a price of HKD 57.97 per share [1] Group 1: Offering Details - The global offering consisted of 31.6104 million H-shares, with 8.7% allocated to public offering and 91.3% to international offering [1] - The public offering in Hong Kong was oversubscribed by 101.06 times, while the international offering was oversubscribed by 16.7 times [1] - Each board lot consists of 200 shares, and trading of the H-shares is expected to commence on January 9, 2026, at 9:00 AM on the Hong Kong Stock Exchange [1]